Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress
29 août 2022 08h00 HE
|
Timber Pharmaceuticals
- Company announces positive clinical data of FDA-Designated Breakthrough Therapy TMB-001 demonstrating safety, efficacy and quality of life improvements in congenital ichthyosis patients will be...
Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology
26 août 2022 08h00 HE
|
Timber Pharmaceuticals
- Previously reported study demonstrated clinically meaningful efficacy with a favorable safety profile for TMB-001 in moderate to severe congenital ichthyosis - - Company has since initiated pivotal...
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results
11 août 2022 17h20 HE
|
Timber Pharmaceuticals
Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING RIDGE, NJ, Aug. 11, 2022 (GLOBE NEWSWIRE) --...
Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering
08 août 2022 16h05 HE
|
Timber Pharmaceuticals
Basking Ridge, NJ, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
04 août 2022 09h21 HE
|
Timber Pharmaceuticals
Basking Ridge, NJ, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis
23 juin 2022 08h00 HE
|
Timber Pharmaceuticals
Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ,...
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis
31 mai 2022 08h00 HE
|
Timber Pharmaceuticals
- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber"...
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results
12 mai 2022 16h10 HE
|
Timber Pharmaceuticals
Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022 BASKING RIDGE, NJ, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber...
Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis
28 avr. 2022 08h00 HE
|
Timber Pharmaceuticals
Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days BASKING RIDGE, NJ, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber...
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results
31 mars 2022 17h44 HE
|
Timber Pharmaceuticals
Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022 BASKING RIDGE, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...